Elutia raises $26m without new shares as it readies NXT-41x FDA filing

Elutia reported on 5 November that it had brought in $26 million without selling any equity. The money came from three sources: a loan, the sale of a business and the release of funds held in escrow. The company's summary did not give the loan terms, the size of each component or the identity of the business sold.

The funding sits alongside a pipeline milestone. Elutia said a rabbit study conducted to good laboratory practice standards on NXT-41x, an implantable biologic material carrying an antibiotic layer for reconstructive and breast surgery, achieved its goals. The company said no live MRSA or E. coli bacteria were found in the animals. The result is company-reported, and the full dataset has not been published.

Elutia intends to file NXT-41x with the US Food and Drug Administration in the last three months of 2026 and is aiming for clearance in the first half of 2027. That timetable depends on the agency's review. The company also expects an FDA decision this quarter on NXT-41, the version of the material without the antibiotic.

The only revenue figure in the summary was for cardiovascular products, where sales rose 20% to $1.1 million. The source material did not say how that compares with the company's total sales. It also did not describe the study design or the regulatory route NXT-41x will take.